EP2180884A4 - Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc - Google Patents

Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc

Info

Publication number
EP2180884A4
EP2180884A4 EP08794800.6A EP08794800A EP2180884A4 EP 2180884 A4 EP2180884 A4 EP 2180884A4 EP 08794800 A EP08794800 A EP 08794800A EP 2180884 A4 EP2180884 A4 EP 2180884A4
Authority
EP
European Patent Office
Prior art keywords
treatment
therapeutic agents
stable formulations
cns diseases
central administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08794800.6A
Other languages
German (de)
English (en)
Other versions
EP2180884A1 (fr
Inventor
Karen E Stevens
Daniel J Abrams
Tom Anchordoquy
Raymond Bunch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado System
Original Assignee
University of Colorado System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado System filed Critical University of Colorado System
Publication of EP2180884A1 publication Critical patent/EP2180884A1/fr
Publication of EP2180884A4 publication Critical patent/EP2180884A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08794800.6A 2007-07-25 2008-07-25 Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc Withdrawn EP2180884A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96655407P 2007-07-25 2007-07-25
PCT/US2008/009109 WO2009014762A1 (fr) 2007-07-25 2008-07-25 Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc

Publications (2)

Publication Number Publication Date
EP2180884A1 EP2180884A1 (fr) 2010-05-05
EP2180884A4 true EP2180884A4 (fr) 2013-04-17

Family

ID=40281688

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08794800.6A Withdrawn EP2180884A4 (fr) 2007-07-25 2008-07-25 Administration par voie centrale de formulations stables d'agents thérapeutiques pour traiter des affections du snc

Country Status (4)

Country Link
EP (1) EP2180884A4 (fr)
AU (1) AU2008279636A1 (fr)
CA (1) CA2694122A1 (fr)
WO (1) WO2009014762A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008095221A1 (fr) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Traitement du syndrome hypercinétique
CA2720254A1 (fr) * 2008-04-01 2009-12-17 Regents Of The University Of Colorado, A Body Corporate Procedes et compositions pour l'administration intracerebroventriculaire de felbamate
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
US11511035B2 (en) 2016-07-28 2022-11-29 Cerebral Therapeutics, Inc. Implantable intraventricular sampling and infusion access device
US20190151239A1 (en) 2016-07-28 2019-05-23 Cerebral Therapeutics LLC Infusing drug solution directly into brain fluid
CN111263634A (zh) * 2017-10-23 2020-06-09 智力疗法有限公司 用于治疗神经障碍的高浓度丙戊酸溶液
EP3520803A1 (fr) * 2018-01-31 2019-08-07 Zarodex Therapeutics Limited Nouvelles utilisations
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
US12551669B2 (en) 2020-07-15 2026-02-17 Biogen Ma Inc. Medical system including two access ports
IL299904B1 (en) 2020-07-20 2026-05-01 Cerebral Therapeutics Inc Liquid catheter device for recording brain status
US12102636B2 (en) * 2021-02-11 2024-10-01 Medtronic, Inc. Administration of antipsychotics
US12605537B2 (en) 2022-02-15 2026-04-21 Biogen Ma Inc. Implantable medical device for use with or having recording electrode

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400609A1 (fr) * 1989-06-02 1990-12-05 Ciba-Geigy Ag Solutions intraveineuses à déclenchement d'action rapide
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2007084541A2 (fr) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Administration centrale de formulations stables d'agents thérapeutiques dans le traitement d'affections du système nerveux central (snc)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2716680B1 (fr) * 1994-02-25 1996-04-05 Adir Nouveaux dérivés de benzodioxane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US7528108B2 (en) * 2005-04-26 2009-05-05 Ambryx Biotechnology, Inc. Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0400609A1 (fr) * 1989-06-02 1990-12-05 Ciba-Geigy Ag Solutions intraveineuses à déclenchement d'action rapide
US20050090548A1 (en) * 2003-10-23 2005-04-28 Medtronic, Inc. Intrathecal gabapentin for treatment of epilepsy
WO2007084541A2 (fr) * 2006-01-17 2007-07-26 Regents Of The University Of Colorado Administration centrale de formulations stables d'agents thérapeutiques dans le traitement d'affections du système nerveux central (snc)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JANG J ET AL: "USE OF 2 HYDROXYPROPYL-BETA-CYCLODEXTRIN AS AN INTRATHECAL DRUG VEHICLE WITHOPIOIDS", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 261, no. 2, 1 January 1992 (1992-01-01), pages 592 - 600, XP008085290, ISSN: 0022-3565 *
See also references of WO2009014762A1 *
YAKSH T L ET AL: "The utility of 2-hydroxypropyl-beta-cyclodextrin as a vehicle for the intracerebral and intrathecal administration of drugs", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 48, no. 7, 1 January 1991 (1991-01-01), pages 623 - 633, XP025549532, ISSN: 0024-3205, [retrieved on 19910101], DOI: 10.1016/0024-3205(91)90537-L *

Also Published As

Publication number Publication date
WO2009014762A1 (fr) 2009-01-29
CA2694122A1 (fr) 2009-01-29
AU2008279636A1 (en) 2009-01-29
EP2180884A1 (fr) 2010-05-05

Similar Documents

Publication Publication Date Title
EP1848270A4 (fr) Administration par voie transmuqueuse de compositions medicamenteuses pour le traitement et la prevention de troubles chez les animaux
FR22C1062I2 (fr) Thérapie de remplacement enzymatique d&#39;escalade de doses pour le traitement du déficit en sphingomyélinase acide
EP2049137A4 (fr) Les salicylanilides renforcent l&#39;administration par voie orale de peptides thérapeutiques
EP2007435A4 (fr) Système pour l&#39;administration ciblée d&#39;agents thérapeutiques
EP2164518A4 (fr) Formulations pour l&#39;administration par voie orale d&#39;agents thérapeutiques, et procédés associés
EP2151435A4 (fr) Composition pharmaceutique pour le traitement de la maladie d&#39;alzheimer
EP2259782A4 (fr) Formulations pharmaceutiques de resvératrol et procédés d&#39;utilisation de celles-ci pour traiter des troubles cellulaires
EP2107909A4 (fr) Composes et compositions pharmaceutiques destines au traitement des troubles hepatiques
WO2007038209A3 (fr) Antagonistes du mglur1 tetracycliques fusionnes utilises en tant qu&#39;agents therapeutiques
EP1971372A4 (fr) Compositions de supports a noyau hydrophobe pour l&#39;administration d&#39;agents therapeutiques, et procedes de preparation et d&#39;utilisation
EP1991268A4 (fr) Polymorphismes des gènes de la voie de l&#39;angiogenèse pour choix de thérapie
EP2268647A4 (fr) Composés et compositions pour la détection et le traitement de la maladie d&#39;alzheimer et des troubles associés
ZA200810194B (en) &#34;use of arylcarboxylic acid biphenylmides for seed treatment&#34;
EP1848431A4 (fr) Formulations liquides pour le traitement de maladies ou affections
MA32898B1 (fr) Modulateurs allosteriques positifs du recepteur m1 d&#39;arylmethylbenzoquinazolinone
EP2588130A4 (fr) Administration au snc d&#39;agents thérapeutiques
EP2564845A4 (fr) Médicament pour traiter des affections hyperplasiques et inflammatoires chez l&#39;humain à base de diindolylméthane
EP1807146A4 (fr) Composition pour l&#39;amelioration de l&#39;efficacite d&#39;administration de medicaments
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
IL192841A0 (en) Central administration of stable formulations of therapeutic agents for cns conditions
EP2036565A4 (fr) Préparation pour application cutanée contenant de l&#39;acide triterpénique
FR13C0029I2 (fr) Compositions pour le traitement de troubles gastro-intestinaux
EP2217216A4 (fr) Préparation à biodisponibilité accrue pour administration orale d&#39;agents polaires
EP1758854A4 (fr) Composes pyrrolidin-3-yle utiles en tant qu&#39;inhibiteurs de la beta-secretase pour le traitement de la maladie d&#39;alzheimer
FR2906140B1 (fr) Forme galenique pour l&#39;administration par voie trans-muqueuse de principes actifs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100223

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130320

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20060101ALI20130314BHEP

Ipc: A61K 47/40 20060101ALI20130314BHEP

Ipc: A61K 9/22 20060101AFI20130314BHEP

17Q First examination report despatched

Effective date: 20140507

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170823